Hematologic Malignancy
Lymphoid Leukemia
CI-CAN-00001101Explore in graph →
Hematologic827 active trials20 approved drugs95 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001101Explore in graph →
Clinical trials
3,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (489)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02345915 | Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia(LEA-JA) | unknown | N/A | 90 | Institut Paoli-CalmettesOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT03249636 | New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT03166878 | A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jun 23, 2017 | clinicaltrials |
| NCT03191773 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | unknown | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02660762 | Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT03150849 | C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia | unknown | — | 50 | Assiut UniversityOTHER | 0 | May 12, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT03035344 | Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL) | unknown | — | 25 | Aristotle University Of ThessalonikiOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL(CCFMPCA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT03022747 | Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol | unknown | Phase 2 | 60 | Vastra Gotaland RegionOTHER_GOV | 2 | Jan 16, 2017 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02892695 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02968472 | A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia | unknown | Phase 1 | 30 | The First People's Hospital of YunnanOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02819583 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Oct 25, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02894645 | Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | unknown | Phase 4 | 500 | National University Hospital, SingaporeOTHER | 2 | Sep 30, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02766868 | Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL | unknown | Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT02828774 | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia | unknown | — | 30 | Assuta Medical CenterOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02759822 | Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias | unknown | — | 30 | Leonardo Javier ArcuriOTHER_GOV | 1 | May 3, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02413021 | The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | unknown | Phase 1 | 40 | Isfahan University of Medical SciencesOTHER | 0 | Feb 25, 2016 | clinicaltrials |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19(CART19) | unknown | N/A | 12 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01873807 | HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL(HITA) | unknown | Phase 4 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2015 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
| NCT01423500 | ALL-SCT BFM International- HSCT in Children and Adolescents With ALL(ALL-SCT-BFMi) | unknown | Phase 3 | 405 | St. Anna KinderkrebsforschungOTHER | 11 | Jun 26, 2015 | clinicaltrials |
| NCT01423747 | Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia | unknown | Phase 3 | 400 | St. Anna KinderkrebsforschungOTHER | 2 | Jun 26, 2015 | clinicaltrials |
| NCT02360930 | Vincristine PK and PD in the AYA Population Compared to Younger Children | unknown | — | 30 | Children's Hospital Los AngelesOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01521689 | Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment(LLCRlowdoz) | unknown | Phase 2 | 35 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT02377869 | Heavy Light Chain in Chronic Lymphocytic Leukemia | unknown | — | 130 | Bnai Zion Medical CenterOTHER_GOV | 1 | Mar 4, 2015 | clinicaltrials |
| NCT02339350 | Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children | unknown | Phase 2 | 110 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Jan 16, 2015 | clinicaltrials |
| NCT02290132 | ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors(HSCT) | unknown | — | 63 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02267590 | Tissue Collection for Biomarkers Determining Resistance to Ibrutinib(CLARITY) | unknown | — | 120 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT02070523 | Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: | unknown | Phase 3 | 200 | Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.OTHER | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01354457 | Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+(RIT 90YEpra) | unknown | Phase 1 / Phase 2 | 21 | Nantes University HospitalOTHER | 1 | Jun 25, 2014 | clinicaltrials |
| NCT02156726 | Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project(Q-lite) | unknown | — | 200 | Czech CLL Study GroupNETWORK | 1 | Jun 5, 2014 | clinicaltrials |
| NCT02007811 | Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination(B-cell therapy) | unknown | Phase 1 / Phase 2 | 15 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 26, 2014 | clinicaltrials |
| NCT01619124 | Osteonecroses in Pediatric Patients With ALL(OPAL) | unknown | — | 400 | Klinik für Kinder-Onkologie, -Hämatologie und Klinische ImmuOTHER | 1 | Mar 5, 2014 | clinicaltrials |
| NCT02072785 | Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia(LY01609) | unknown | Phase 3 | 480 | Nanjing Luye Sike Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 3, 2014 | clinicaltrials |
| NCT01990807 | Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia | unknown | Phase 4 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01307241 | RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML | unknown | — | 50 | National Institute of CancerologíaOTHER_GOV | 1 | Nov 15, 2013 | clinicaltrials |
| NCT01272440 | A Drug Monitoring Study on PEG-asparaginase Treatment in Children Diagnosed Acute Lymphoblastic Leukaemia | unknown | — | 200 | Aarhus University HospitalOTHER | 1 | Nov 13, 2013 | clinicaltrials |
| NCT01849939 | Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia(RICAC) | unknown | Phase 2 | 43 | University Hospital, Clermont-FerrandOTHER | 1 | May 9, 2013 | clinicaltrials |
| NCT01678430 | A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment(RIAltO) | unknown | Phase 3 | 670 | University of LiverpoolOTHER | 1 | Oct 15, 2012 | clinicaltrials |
| NCT00982514 | Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 | unknown | — | 60 | Oslo University HospitalOTHER | 1 | Sep 12, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Sep 5, 2017source: clinicaltrials